Paclitaxel for injection (albumin bound)
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Zhejiang Cancer Hospital, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Risen (Suzhou) Pharma Tech Co., Ltd., Liaoning Cancer Hospital & Institute
Conditions
Advanced Pancreatic CancerAdvanced Solid TumorsEsophageal Squamous Cell CarcinomaMetastatic Cervical CancerNon Small Cell Lung CancerPancreatic CarcinomaRecurrent Cervical CancerTriple Negative Breast Cancer
Phase 1
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
NCT04506138
Start: 2020-08-11End: 2025-12-31Target: 46Updated: 2021-12-14
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
TerminatedNCT05193604
Start: 2022-03-24End: 2023-11-27Updated: 2023-12-08
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
RecruitingNCT06208410
Start: 2024-01-11End: 2027-02-26Target: 306Updated: 2025-07-25
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
RecruitingNCT06821503
Start: 2025-04-11End: 2028-12-01Target: 72Updated: 2026-03-10
Phase 2
Phase 3
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
NCT04405505
Start: 2020-06-01End: 2022-07-01Target: 332Updated: 2020-05-28
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Not yet recruitingNCT07418749
Start: 2026-03-01End: 2028-12-01Target: 398Updated: 2026-02-18